Kohjin Bio Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
Kohjin Bio Co., Ltd. carries a market capitalization of 5.03B, placing it among publicly traded companies globally. Its enterprise value stands at 7.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.03B |
| Enterprise Value | 7.63B |
Share Statistics
Kohjin Bio Co., Ltd. currently has 5.11M shares outstanding.
| Shares Outstanding | 5.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kohjin Bio Co., Ltd. trades at a trailing price-to-earnings ratio of 49.69. The price-to-sales ratio is 7.21, and the price-to-book ratio stands at 2.21.
| PE Ratio | 49.69 |
| PS Ratio | 7.21 |
| PB Ratio | 2.21 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Kohjin Bio Co., Ltd. trades at an EV/EBITDA multiple of 33.78 and an EV/FCF ratio of 1,629.53. The EV/Sales ratio of 6.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.78 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.23 |
| EV / EBITDA | 33.78 |
| EV / EBIT | 33.78 |
| EV / FCF | 1,629.53 |
Financial Position
Kohjin Bio Co., Ltd. maintains a current ratio of 2.01, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.78, indicating elevated leverage, while an interest coverage ratio of 36.08 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.01 |
| Quick Ratio | 1.35 |
| Debt / Equity | 39.78 |
| Debt / EBITDA | 9.30 |
| Interest Coverage | 36.08 |
Taxes
Over the trailing twelve months, Kohjin Bio Co., Ltd. has paid 59.92M in income taxes, reflecting an effective tax rate of 25.20.
| Income Tax | 59.92M |
| Effective Tax Rate | 25.20 |
Stock Price Statistics
Kohjin Bio Co., Ltd.'s stock has declined approximately -41.39369% over the past 52 weeks. The 50-day moving average sits at 1,299.86, while the 200-day moving average is 1,419.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -41.39369% |
| 50-Day Moving Average | 1,299.86 |
| 200-Day Moving Average | 1,419.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kohjin Bio Co., Ltd. generated 1.23B in revenue and converted that into 177.84M in net income, yielding earnings per share of 36.74. EBITDA reached 225.85M, while operating income came in at 225.85M.
| Revenue | 1.23B |
| Gross Profit | 571.26M |
| Operating Income | 225.85M |
| Pretax Income | 237.76M |
| Net Income | 177.84M |
| EBITDA | 225.85M |
| EBIT | 225.85M |
| Earnings Per Share (EPS) | 36.74 |
Balance Sheet
Kohjin Bio Co., Ltd. holds 3.31B in cash and equivalents against 2.10B in total debt, resulting in a net debt position of -1.21B. Total book value stands at 4.00B, with working capital of 2.48B providing operational flexibility.
| Cash & Cash Equivalents | 3.31B |
| Total Debt | 2.10B |
| Net Debt | -1.21B |
| Equity (Book Value) | 4.00B |
| Book Value Per Share | 826.69 |
| Working Capital | 2.48B |
Margins
Kohjin Bio Co., Ltd. operates with a gross margin of 46.61, reflecting its pricing power and cost economics. The operating margin of 18.43 and net profit margin of 14.51 provide insight into operational efficiency.
| Gross Margin | 46.61 |
| Operating Margin | 18.43 |
| Pretax Margin | 19.40 |
| Profit Margin | 14.51 |
| EBITDA Margin | 18.43 |
Scores
Kohjin Bio Co., Ltd. posts an Altman Z-Score of 2.67, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.67 |